Portfolio manager comments — Q4 2024
Fund performance was negative in Q4. Several of the fund’s holdings within technology and banks posted strength and the Danish IT consultancy Netcompany contributed positively on the back of good results for the period with stable growth and higher than expected margins. Handelsbanken and DNB also contributed as the net interest income remained at a good level. DNB also announced an acquisition of the investment bank Carnegie to broaden its operations and expand within commission-based revenues. The medical technology company Embla, which is a leader within advanced prosthetics, contributed positively after a strong report.
Fund returns were primarily weighed down by the holding in Novo Nordisk after a Phase 3 clinical trial for Cagrisema, a new obesity drug, did not meet the high expectations set by the market and the company. The holding in manufacturing companies, such as Nibe, Kone and Sandvik, had a negative impact on returns due to further weak demand within their end markets.
The fund added a new holding in Autoliv during the quarter. The company showed stable earnings during Q3 despite weak auto production. Autoliv is a supplier of safety equipment that is less affected by the technology choices made in the transition to lower emissions but benefits from increased safety requirements. We increased the holding in Danish Novonesis as the company is showing further strong organic growth for biosolutions, enzymes and microbes that are used in consumer products as well as in industrial and agricultural processes. At the same time, we decreased the holdings in banks, Assa Abloy and Volvo after a period of strong share price performance.
For the upcoming reporting period we will continue to focus on investee companies that have sustainable business models and competitive offers with sustainable growth.